Psychiatry AtlasMedication guide · United States

Opioid medicine for opioid use disorder

Buprenorphine-containing treatments (Subutex, Suboxone, Sublocade, Brixadi)

Generic name
buprenorphine; selected oral-mucosal products contain buprenorphine hydrochloride, with or without naloxone hydrochloride
Brand names
Subutex; Suboxone; Sublocade; Brixadi
Medication class
Opioid medicine for opioid use disorder
Forms covered
Generic buprenorphine sublingual tablets; Suboxone buprenorphine/naloxone film; Sublocade monthly subcutaneous injection; Brixadi weekly subcutaneous injection; Brixadi monthly subcutaneous injection

Article updated: 2026-10-24 · Sources last checked: 2026-11-05

Medication Safety Alerts

Look-alike / sound-alike name

High Alert

  • Acute, community/ambulatory and long-term care: opioid dosing or administration errors can cause life-threatening breathing suppression. Products and routes are not interchangeable.

FDA Boxed Warning

Sublocade and Brixadi injections only.

For Sublocade and Brixadi injections: intravenous administration can cause serious harm or death. These products must be given subcutaneously by healthcare professionals and are available through their respective restricted REMS programs. This injection-specific boxed warning does not apply to the selected sublingual tablets or Suboxone film, which retain their other serious opioid warnings.

Buprenorphine treats opioid use disorder. Sublingual medicine, buprenorphine/naloxone film and weekly or monthly injections have distinct initiation, conversion and safety requirements.

Subutex (historical brand).

What to expect: Treatment aims to reduce withdrawal and cravings and support ongoing recovery.

Warning signs · Medicine forms
Sources last checked:
2026-11-05

What is this medicine used for?

FDA-approved uses

  • Opioid use disorder — Adults. Product-specific induction and maintenance with support.Generic buprenorphine sublingual tablets; Suboxone buprenorphine/naloxone film.
  • Moderate to severe opioid use disorder — Adults meeting prior-treatment criteria. Tolerability and prior-treatment rules differ; Brixadi monthly is not for new untreated patients.Sublocade monthly subcutaneous injection; Brixadi weekly subcutaneous injection; Brixadi monthly subcutaneous injection.

What should I expect?

Treatment aims to reduce withdrawal and cravings and support ongoing recovery. Starting too soon after another opioid can suddenly worsen withdrawal, so initiation depends on clinical assessment.

A useful maintenance plan should control symptoms without excessive sedation. Treatment may continue as long as it benefits you; there is no requirement to taper simply because you have been stable.

How do I take it safely?

Initiation and switching are clinician-directed. The right timing depends on prior opioids and signs of withdrawal; starting too soon can trigger severe withdrawal. Methadone-to-buprenorphine changes require particular planning.

Let prescribed sublingual tablets or film dissolve completely; do not cut, chew or swallow them. Suboxone film may be used under the tongue or, for maintenance as directed, inside the cheek. Avoid eating or drinking until dissolved, then rinse gently with water and swallow; wait at least one hour before brushing.

Sublocade and Brixadi are different healthcare-administered injections with distinct eligibility and conversion rules. They must never be injected into a vein. Do not handle or remove a depot yourself. Contact the clinic about any missed injection; do not double an oral dose.

Alcohol, benzodiazepines and other sedatives raise overdose risk. Do not abruptly change them or abandon opioid treatment; the clinicians should coordinate care. Keep an overdose-reversal medicine accessible and ensure close contacts know how to use it. Store oral products securely away from children.

Monitor liver health, breathing, sedation, cravings, injection sites and dental health. Moderate or severe liver disease can rule out depot products or change oral-product choice. Discuss pregnancy and breastfeeding; newborn withdrawal may occur but untreated opioid use also carries risk. Plan any stopping gradually, with relapse prevention and follow-up; depot withdrawal can be delayed for months.

A naloxone allergy excludes combination products containing naloxone. Tell the team about latex allergy because Brixadi packaging contains natural rubber latex.

Do not use this product after a known allergy to its active medicine or ingredients; tell the pharmacist about previous medication reactions.

What side effects should I know about?

  • Constipation, nausea, headache, sweating, sedation and injection-site reactions.

Tell your prescriber about effects that are persistent, troublesome, or interfere with daily life.

Which warning signs need help?

  • Very slow or absent breathing, inability to wake, blue or gray lips or collapse is an emergency. Call emergency services, give an available opioid overdose-reversal medicine as instructed and stay with the person. Repeat rescue doses may be needed because the opioid can last longer than the reversal medicine.
  • Sublocade and Brixadi have injection-specific boxed warnings: giving them into a vein can cause serious harm or death. Their restricted programs require healthcare administration. Alcohol and sedatives can increase overdose risk with every formulation.
  • Severe allergy needs emergency care. Report jaundice, a severe injection-site reaction or marked weakness with dizziness promptly. Liver injury, adrenal-hormone deficiency, serotonin syndrome and sudden withdrawal during initiation are other important risks.

What else should I know to stay safe?

  • Initiation and opioid switching require clinical supervision: starting too soon can precipitate severe withdrawal, especially after methadone or other long-acting opioids. Sublocade and Brixadi have different eligibility and conversion rules; do not manipulate or remove an injection depot.
  • Check all sedatives and other medicines with the treatment team; do not abruptly change them or abandon opioid treatment. Keep overdose-reversal medicine available, teach close contacts to use it and secure oral products away from children. Any stopping needs a gradual plan and relapse support; depot withdrawal can be delayed.
  • Monitor liver health, breathing, sedation, cravings, injection sites and dental health. Moderate or severe liver impairment may rule out depot products. Discuss pregnancy and breastfeeding; newborn withdrawal can occur. Buprenorphine or product allergy excludes use, naloxone allergy excludes combination products, and Brixadi packaging contains natural rubber latex.
  • Dissolving products can damage teeth. After they dissolve, gently rinse with water and swallow; wait at least one hour before brushing, and maintain dental follow-up.

Urgent help and crisis support · Emergency & Crisis Resources (US)

What can help day to day?

  • Needing long-term treatment does not mean it has failed. Continued protection from withdrawal and return to opioid use can be a treatment benefit.
  • Naloxone in Suboxone does not replace an overdose-rescue medicine. Discuss rescue access and teach people close to you how to respond.
  • Dissolving products need dental care: rinse gently with water after dissolution and wait at least an hour before brushing.

How does it work?

Buprenorphine partly activates opioid receptors, the receiving sites also used by opioids such as morphine and heroin. This can reduce craving and withdrawal without the full activation produced by some other opioids. It can still dangerously slow breathing, especially with other sedating substances.

Explore medication science

How was this medicine developed?

Subutex sublingual treatment was approved for opioid dependence in 2002, followed by Suboxone film in 2010. Sublocade in 2017 and Brixadi in 2023 added different long-acting injection systems.

How do I say the name?

Buprenorphine-containing treatments: byoo-pre-NOR-feen. Capital letters show the stressed syllable.

Medicine forms and official information

Match the full name, release type and route on your prescription. Different formulations need their own prescribing instructions; do not switch or substitute them yourself.

Sources and References

Sources support the U.S. products described here. Product instructions can differ; use the information supplied with your own medicine.

  1. Buprenorphine-containing treatments: current prescribing information — mechanism explanation

    Scope: Mechanism explanation only. Source sections checked: 12.1 Mechanism of Action; 12.2 Pharmacodynamics: Subjective Effects and Effect of Naloxone; 5.2 Risk of Life-Threatening Respiratory and Central Nervous System Depression; 5.10 Precipitation of Opioid Withdrawal Signs and Symptoms..

  2. Buprenorphine-containing treatments: FDA approval history
  3. Buprenorphine-containing treatments: patient medicine information
  4. Generic buprenorphine sublingual tablets: current prescribing information
  5. SUBLOCADE — buprenorphine solution: prescribing information

    Scope: Mechanism explanation only. Source sections checked: 9.2 Abuse: Depot formation and release; 12.3 Pharmacokinetics..

  6. Brixadi prescribing information
  7. Subutex FDA approval history
  8. Sublocade FDA approval history
  9. Brixadi FDA approval history
  10. Sublocade updated FDA prescribing information
  11. Sublocade: Package Insert / Prescribing Information / MOA
  12. Buprenorphine-containing treatments: FDA prescribing information
  13. Methadone: prescribing information
  14. Brixadi updated FDA prescribing information
  15. SAMHSA current medication-treatment regulations and waiver elimination
  16. Buprenorphine-containing treatments: verified neutral parent, PubChem CID 644073
  17. Initiating Buprenorphine Treatment in the Emergency Department — mechanism explanation

    Scope: Mechanism explanation only. Source sections checked: How does buprenorphine work?..

  18. ISMP List of Confused Drug Names
  19. ISMP List of High-Alert Medications in Acute Care Settings
  20. ISMP List of High-Alert Medications in Community/Ambulatory Care Settings
  21. High-Alert Medications in Long-Term Care (LTC) Settings
  22. Frequently Asked Questions about Labeling for Prescription Medicines | FDA
  23. Serotonin syndrome: MedlinePlus Medical Encyclopedia
  24. Monitoring a person during and after antidepressant switching – NHS SPS - Specialist Pharmacy Service – The first stop for professional medicines advice

Giving medicine safely to children: family guide (PDF, 3 pages)

How information is checked

Was this article helpful?

Was this article helpful?

Sends your choice, article identifier, edition and optional issue to Psychiatry Atlas. No name, email or medical details are requested. Daily network codes help prevent spam; hosting may process technical information. This is not a promise of anonymity. Privacy details.

Enable JavaScript to send feedback.

Suggest a missing topic or describe a correction. Please keep personal medical information out of website feedback.

Back to top